Precigen Reported Q2 Revenue for Papzimeos
The Germantown-based biopharmaceutical firm generated $53.1 million from its immunotherapy drug in the second quarter of 2026.
Updated on Oct. 13, 2026 in Biotech
Live Poll
Should local governments prioritize investments to attract and expand the biotech industry in your area?
Precigen reported $53.1 million in net revenue for its immunotherapy drug Papzimeos during the second quarter of 2026. The drug, which treats recurrent respiratory papillomatosis, received FDA approval in August 2025.
Why it matters
The company expanded its Germantown facility to meet high demand for the drug following clinical trials conducted between 2021 and 2024. Local government support has played a key role in the firm's growth as it focuses on treatments for rare diseases.
Precigen employed 175 people as of late July 2026 to support its operations and research efforts. The company continues to utilize its Germantown location to manage the production and development of its precision medicines.
The players
Precigen
This biopharmaceutical company has traded on the stock market under the ticker PGEN since 2020.
National Institutes of Health
This primary agency of the United States government is responsible for biomedical and public health research.
The details
Precigen collaborates with the National Institutes of Health and regional universities to advance its research for rare, difficult-to-treat diseases. The firm expanded its physical footprint in Germantown as a direct result of the clinical trial success and rising market demand for Papzimeos.
Timeline
Clinical trials for Papzimeos occurred from 2021 to 2024.
The FDA granted approval for Papzimeos in August 2025.
As of late July 2026, the company employed 175 people.
Precigen reported $53.1 million in net revenue during Q2 2026.
The Tech Race
Precigen operates within a sector increasingly reliant on institutional partnerships to bridge the gap between early-stage clinical research and commercial viability. This strategy allows smaller biotech firms to leverage established scientific expertise to compete in the precision medicine market.
The expansion of the Germantown facility reflects the increased availability of treatments for patients suffering from rare respiratory conditions. Residents may see continued economic growth in the area as the firm scales its workforce to support its drug production requirements.
The takeaway
Precigen's growth highlights the importance of localized government support in fostering the biotech sector for rare disease research. Investors and patients should monitor how the company balances its facility expansions with the ongoing demand for specialized immunotherapy drugs.
Further reading
Learn more about the latest industry developments in the Biotech section.
Source note: This article includes information reported by Bethesda Magazine.
Live Poll
Should local governments prioritize investments to attract and expand the biotech industry in your area?
